Leerink Partnrs Brokers Lower Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Leerink Partnrs decreased their Q2 2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will earn ($0.12) per share for the quarter, down from their prior estimate of $0.19. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.23 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. Sarepta Therapeutics’s revenue was up 63.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.44) earnings per share.

SRPT has been the subject of a number of other reports. Royal Bank of Canada upped their target price on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. dropped their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday. Citigroup increased their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. UBS Group increased their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, TheStreet upgraded Sarepta Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 4th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $160.60.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $133.66 on Monday. The business has a fifty day simple moving average of $125.63 and a 200 day simple moving average of $110.76. The company has a current ratio of 4.05, a quick ratio of 3.45 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $12.63 billion, a price-to-earnings ratio of 1,215.09 and a beta of 0.95. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $159.89.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at $28,000. Riggs Asset Managment Co. Inc. raised its stake in Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares in the last quarter. Montag A & Associates Inc. bought a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $30,000. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 154 shares during the last quarter. Finally, Principal Securities Inc. purchased a new stake in Sarepta Therapeutics in the fourth quarter worth approximately $26,000. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.